TONIX Pharmaceuticals, Inc. Announces The Enrollment Of Completers From The BESTFIT Trial Into A 12-Month Open-Label Extension Study
12/10/2013 9:11:18 AM
NEW YORK, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, announced today that it is enrolling subjects into an open-label extension (OLE) study to the BESTFIT trial of TNX-102 2.8 mg sublingual tablet (SL) in fibromyalgia (FM).
Help employers find you! Check out all the jobs and post your resume.
comments powered by